Skip to main content
. 2019 Mar 22;17(5):4013–4022. doi: 10.3892/etm.2019.7428

Figure 3.

Figure 3.

Changes in body weight of groups during the study period. *P<0.001 compared with the Metformin + PDE4i group (at the end of the study); &P=0.006 compared with the Metformin group (at the end of the study). PCOS, polycystic ovary syndrome; PDE4i, phosphodiesterase 4 inhibitor.